1.
|
DeAngelis LM: Brain tumors. N Engl J Med.
344:114–123. 2001. View Article : Google Scholar
|
2.
|
Kim SM, Lim JY, Park SI, et al: Gene
therapy using TRAIL-secreting human umbilical cord blood-derived
mesenchymal stem cells against intracranial glioma. Cancer Res.
68:9614–9623. 2008. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Kinoshita Y, Kamitani H, Mamun MH, et al:
A gene delivery system with a human artificial chromosome vector
based on migration of mesenchymal stem cells towards human
glioblastoma HTB14 cells. Neurol Res. 2009, (E-pub ahead of
print).
|
4.
|
Kucerova L, Altanerova V, Matuskova M,
Tyciakova S and Altaner C: Adipose tissue-derived human mesenchymal
stem cells mediated prodrug cancer gene therapy. Cancer Res.
67:6304–6313. 2007. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Lee J, Elkahloun AG, Messina SA, et al:
Cellular and genetic characterization of human adult bone
marrow-derived neural stem-like cells: a potential antiglioma
cellular vector. Cancer Res. 63:8877–8889. 2003.PubMed/NCBI
|
6.
|
Menon LG, Kelly K, Yang HW, Kim SK, Black
PM and Carroll RS: Human bone marrow-derived mesenchymal stromal
cells expressing S-TRAIL as a cellular delivery vehicle for human
glioma therapy. Stem Cells. 27:2320–2330. 2009. View Article : Google Scholar : PubMed/NCBI
|
7.
|
Miletic H, Fischer YH, Litwak S, et al:
Bystander killing of malignant glioma by bone marrow-derived
tumor-infiltrating progenitor cells expressing a suicide gene. Mol
Ther. 15:1373–1381. 2007. View Article : Google Scholar : PubMed/NCBI
|
8.
|
Nakamizo A, Marini F, Amano T, et al:
Human bone marrow-derived mesenchymal stem cells in the treatment
of gliomas. Cancer Res. 65:3307–3318. 2005.PubMed/NCBI
|
9.
|
Nakamura K, Ito Y, Kawano Y, et al:
Antitumor effect of genetically engineered mesenchymal stem cells
in a rat glioma model. Gene Ther. 11:1155–1164. 2004. View Article : Google Scholar : PubMed/NCBI
|
10.
|
Sasportas LS, Kasmieh R, Wakimoto H, et
al: Assessment of therapeutic efficacy and fate of engineered human
mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA.
106:4822–4827. 2009. View Article : Google Scholar : PubMed/NCBI
|
11.
|
Uchibori R, Okada T, Ito T, et al:
Retroviral vector-producing mesenchymal stem cells for targeted
suicide cancer gene therapy. J Gene Med. 11:373–381. 2009.
View Article : Google Scholar : PubMed/NCBI
|
12.
|
Wu X, Hu J, Zhou L, et al: In vivo
tracking of superparamagnetic iron oxide nanoparticle-labeled
mesenchymal stem cell tropism to malignant gliomas using magnetic
resonance imaging. Laboratory investigation. J Neurosurg.
108:320–329. 2008. View Article : Google Scholar
|
13.
|
Yuan X, Hu J, Belladonna ML, Black KL and
Yu JS: Interleukin-23-expressing bone marrow-derived neural
stem-like cells exhibit antitumor activity against intracranial
glioma. Cancer Res. 66:2630–2638. 2006. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Amano S, Li S, Gu C, et al: Use of
genetically engineered bone marrow-derived mesenchymal stem cells
for glioma gene therapy. Int J Oncol. 35:1265–1270. 2009.PubMed/NCBI
|
15.
|
Gu C, Li S, Tokuyama T, Yokota N and Namba
H: Therapeutic effect of genetically engineered mesenchymal stem
cells in rat experimental leptomeningeal glioma model. Cancer Lett.
298:256–262. 2010. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Bloom J and Pagano M: Deregulated
degradation of the cdk inhibitor p27 and malignant transformation.
Semin Cancer Biol. 13:41–47. 2003. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Philipp-Staheli J, Payne SR and Kemp CJ:
p27(Kip1): regulation and function of a haploinsufficient tumor
suppressor and its misregulation in cancer. Exp Cell Res.
264:148–168. 2001. View Article : Google Scholar : PubMed/NCBI
|
18.
|
Gao Y, Kitagawa K, Hiramatsu Y, et al:
Up-regulation of GPR48 induced by down-regulation of p27Kip1
enhances carcinoma cell invasiveness and metastasis. Cancer Res.
66:11623–11631. 2006. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Rodier G, Montagnoli A, DiMarcotullio L,
et al: p27 cytoplasmic localization is regulated by phosphorylation
on Ser10 and is not a prerequisite for its proteolysis. EMBO J.
20:6672–6682. 2001. View Article : Google Scholar : PubMed/NCBI
|
20.
|
Ishida N, Hara T, Kamura T, Yoshida M,
Nakayama K and Nakayama KI: Phosphorylation of p27Kip1 on serine 10
is required for its binding to CRM1 and nuclear export. J Biol
Chem. 277:14355–14358. 2002. View Article : Google Scholar
|
21.
|
Li S, Tokuyama T, Yamamoto J, Koide M,
Yokota N and Namba H: Bystander effect-mediated gene therapy of
gliomas using genetically engineered neural stem cells. Cancer Gene
Ther. 12:600–607. 2005. View Article : Google Scholar : PubMed/NCBI
|
22.
|
Chen J, Zhang ZG, Li Y, et al: Intravenous
administration of human bone marrow stromal cells induces
angiogenesis in the ischemic boundary zone after stroke in rats.
Circ Res. 92:692–699. 2003. View Article : Google Scholar : PubMed/NCBI
|
23.
|
Nakayama K, Ishida N, Shirane M, et al:
Mice lacking p27(Kip1) display increased body size, multiple organ
hyperplasia, retinal dysplasia, and pituitary tumors. Cell.
85:707–720. 1996. View Article : Google Scholar : PubMed/NCBI
|
24.
|
Nobes CD and Hall A: Rho GTPases control
polarity, protrusion, and adhesion during cell movement. J Cell
Biol. 144:1235–1244. 1999. View Article : Google Scholar : PubMed/NCBI
|
25.
|
Besson A, Gurian-West M, Schmidt A, Hall A
and Roberts JM: p27Kip1 modulates cell migration through the
regulation of RhoA activation. Genes Dev. 18:862–876. 2004.
View Article : Google Scholar : PubMed/NCBI
|
26.
|
Aboody KS, Brown A, Rainov NG, et al:
Neural stem cells display extensive tropism for pathology in adult
brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA.
97:12846–12851. 2000. View Article : Google Scholar : PubMed/NCBI
|
27.
|
Li S, Gao Y, Tokuyama T, et al:
Genetically engineered neural stem cells migrate and suppress
glioma cell growth at distant intracranial sites. Cancer Lett.
251:220–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
28.
|
Xu G, Jiang XD, Xu Y, et al:
Adenoviral-mediated interleukin-18 expression in mesenchymal stem
cells effectively suppresses the growth of glioma in rats. Cell
Biol Int. 33:466–474. 2009. View Article : Google Scholar : PubMed/NCBI
|
29.
|
Ho IA, Chan KY, Ng WH, et al: Matrix
metalloproteinase 1 is necessary for the migration of human bone
marrow-derived mesenchymal stem cells toward human glioma. Stem
Cells. 27:1366–1375. 2009. View
Article : Google Scholar : PubMed/NCBI
|
30.
|
Zhao D, Najbauer J, Garcia E, et al:
Neural stem cell tropism to glioma: critical role of tumor hypoxia.
Mol Cancer Res. 6:1819–1829. 2008. View Article : Google Scholar : PubMed/NCBI
|
31.
|
Bexell D, Gunnarsson S, Tormin A, et al:
Bone marrow multi-potent mesenchymal stroma cells act as
pericyte-like migratory vehicles in experimental gliomas. Mol Ther.
17:183–190. 2009. View Article : Google Scholar : PubMed/NCBI
|
32.
|
Webb DJ and Horwitz AF: New dimensions in
cell migration. Nat Cell Biol. 5:690–692. 2003. View Article : Google Scholar : PubMed/NCBI
|
33.
|
Baldassarre G, Belletti B, Nicoloso MS, et
al: p27(Kip1)-stathmin interaction influences sarcoma cell
migration and invasion. Cancer Cell. 7:51–63. 2005. View Article : Google Scholar : PubMed/NCBI
|